Recent Updates
Recently added Catalysts
ELAN Negative Sentiment Score: 25/100

ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Elanco Animal Health Incorporated regarding potential claims on behalf of long-term stockholders. This follows a class action complaint filed on October 7, 2024, alleging that Elanco’s board breached their fiduciary duties. The complaint specifically accuses Elanco of making materially false statements about the safety of Zenrelia and its inability to meet important timelines for product approvals. This has raised significant concerns about the company's business operations and financial prospects.

Market Sentiment Analysis

CONCERNS & RISKS

  • Elanco is facing a class action complaint alleging misleading statements about the safety of Zenrelia.
  • There are concerns over Elanco's ability to meet its timeline for U.S. approval and launch of Zenrelia and Credelio Quattro.
  • The company's financial prospects may have been overstated, leading to significant investor concern.

Full Press Release Details

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Elanco Animal Health Incorporated (NYSE:ELAN) on behalf of long-term stockholders following a class action complaint that was filed against Elanco on October 7, 2024 with a Class Period from November 7, 2023 to June 26, 2024. Our investigation concerns whether the board of directors of Elanco have breached their fiduciary duties to the company.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Zenrelia was less safe than the Company had led investors to believe; (2) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro; (3) accordingly, the Company's business and/or financial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you are a long-term stockholder of Elanco, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the investigation about Elanco Animal Health?

Bragar Eagel & Squire, P.C. is investigating potential claims against Elanco related to a class action complaint filed on October 7, 2024.

What were the allegations in the Elanco class action?

The Complaint alleges that Elanco made false statements about its safety, approvals, and financial prospects.

Who can participate in the investigation?

Long-term stockholders of Elanco who have information or concerns can participate.

How can I contact Bragar Eagel & Squire, P.C.?

You can contact them via email at investigations@bespc.com or by phone at (212) 355-4648.

Last updated: Apr 30, 2025